Compare ARDX & JQC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ARDX | JQC |
|---|---|---|
| Founded | 2007 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.3M | 705.1M |
| IPO Year | 2014 | 2003 |
| Metric | ARDX | JQC |
|---|---|---|
| Price | $3.24 | $4.61 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $12.90 | N/A |
| AVG Volume (30 Days) | ★ 4.1M | 758.2K |
| Earning Date | 10-29-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 11.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,607,000.00 | N/A |
| Revenue This Year | $19.98 | N/A |
| Revenue Next Year | $27.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.18 | $4.57 |
| 52 Week High | $8.40 | $5.20 |
| Indicator | ARDX | JQC |
|---|---|---|
| Relative Strength Index (RSI) | 29.24 | 40.95 |
| Support Level | N/A | N/A |
| Resistance Level | $3.63 | $4.86 |
| Average True Range (ATR) | 0.11 | 0.06 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 12.50 | 17.50 |
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Nuveen Credit Strategies Income Fund is a diversified closed-end management investment company. Its investment objective is to provide high current income and total return. The fund meets its investment objectives by investing its managed assets in senior secured and second lien loans, and its managed assets across the capital structure of companies (including equity securities) with a primary emphasis on high yield bonds, convertible securities and other forms of income-producing securities.